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The management of aggressive breast cancer, particularly, triple negative breast cancer (TNBC) remains a
formidable challenge, despite treatment advancement. Although newer therapies such as atezolizumab, olaparib,
and sacituzumab can tackle the breast cancer prognosis and/or progression, but achieved limited survival benefit
(s). The current research efforts are aimed to develop and implement strategies for improved bioavailability,
targetability, reduce systemic toxicity, and enhance therapeutic outcome of FDA-approved treatment regimen.
This review presents various nanoparticle technology mediated delivery of chemotherapeutic agent(s) for breast
cancer treatment. This article also documents novel strategies to employ cellular and cell membrane cloaked
(biomimetic) nanoparticles for effective clinical translation. These technologies offer a safe and active targeting
nanomedicine for effective management of breast cancer, especially TNBC.

1. Introduction
Breast cancer (BC) remains the most commonly diagnosed cancer
among women and is the second leading cause of death after lung cancer
in the United States [1]. In 2020, it was estimated that 276,480 new
cases of BC will be diagnosed among women and 42,170 women will be
expected to die due to this disease. Breast cancer begins when the ma
lignant epithelial cells accumulate and grow out. Depending on the re
gion they grow out from, it is classified into non-invasive and invasive.
Non-invasive (carcinoma in-situ) is when the carcinoma is confined in
the lobules and duct. Invasive carcinomas occur when the carcinoma
diffuses to the surrounding connective tissues and metastasize to distant
sites. These carcinomas are divided into ductal and lobular carcinoma,
depending on where the tumor is formed. Ductal carcinomas comprise
two-third of the total BC and arise from the epithelial cells of the ducts,
whereas the lobular carcinoma arises from the lobules and is about
one-third of the total BC cases [2].
Triple negative breast cancer (TNBC) represents the most aggressive
and heterogeneous subtype of BC. Clinically, it is characterized by
negative for expression of estrogen receptor (ER), progesterone receptor

(PR), and human epidermal growth factor receptor 2 (HER2) protein.
Typically, TNBC demonstrates an increased mitotic activity, increased
expression of proliferation markers, high nuclear atypia, high nuclearcytoplasmic ratio, scant stromal content, central necrosis, multiple
apoptotic cells, invasive, and stromal lymphocytic infiltration [3,4].
Additionally, these tumors are also characterized by rapid growth rate,
higher grade, greater chance of lymph node involvement/progression,
and metastasize mostly to the viscera, especially the lungs and the brain
[5]. The distinct cellular phenotype, aggressive nature, metastatic po
tential, and lack of receptor or target [6], makes chemotherapy as a
prefered treatment option for TNBC. However, TNBC with the worst
prognosis and high recurrence rate within the first 5 years of therapy
and shorter overall survival to only 9–13 months [7], in contrast to other
subtypes of BC, which makes therapeutic intervention for TNBC is an
unmet need.
2. Therapeutic strategies for TNBC
As described above, TNBC due to heterogeneity, molecular vari
ability, and stemness [8] has no specific treatment protocol. Although
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the relentless efforts of researchers have led to improvements in the
therapy of TNBC, and newer targets are discovered by studying the
genomic variability. Therapies that have shown promising outcomes in
TNBC, either alone or in combination with neoadjuvant therapy have
been evaluated by clinical trials, are summarized below. Fig. 1 describes
the schematic representation of the various conventional treatment
strategies and emerging treatment trends for TNBC. Although chemo
therapy remains the backbone treatment option for most TNBC patients,
emerging trends are evolved which includes immunotherapy (check
point inhibitors), targeted therapy (inhibitors of various pathways),
antibody conjugates, and novel nanotherapeutic formulation.

26% improvement with treated twice weekly when anthracyclines are
used in combination [15–17]. Although, a higher response rate is ach
ieved with this therapy [16,17] yet higher recurrence rate and overall
low survival rate [18] has limited usage of this type of therapy. Other
associated side effects include acute toxicity such as irreversible car
diotoxicity myelotoxicity, alopecia, nausea, and vomiting [18–20].
Platinum agents have proven to be beneficial for the treatment of
TNBC patients when used in combination or as single agents [21]. These
agents are effective in patients with a breast cancer gene (BRCA) mu
tation. A Phase II clinical trial (NCT00148694) suggests that 21% of
patients received PCR with single-agent cisplatin and 15% response
when excluding the BRCA1 mutations. This indicates the importance of
platinum agents as adjuvant or neoadjuvant therapy in BRCA mutants
[10]. BRCA1 mutant has shown increased sensitivity to platinum agents
because of the ability to repair DNA; however, it may become resistant
and may be required to be used in homologous combination [11].
Another Phase II clinical trial suggests carboplatin and paclitaxel (PTX)
with or without trastuzumab showed a 67% increase in PCR [22]. In
another Phase II clinical trial, cisplatin (CIS) combination with ER and
5-FU in addition to PTX versus without the PTX treatment improved the
response rate by 40% [23]. A higher response rate of 34% was observed
in women treated with platinum and docetaxel (DTX) [24]. Thus, a
combination of platinum agents has been shown to have higher efficacy
than when used alone. Therapy with platinum agents are of special in
terest when treating a TNBC patient with a BRCA defect.
Taxanes either as a single agent or in combination with anthracy
clines have shown to be beneficial in TNBC in contrast to other subtypes
of BC, attaining PCR of up to 40% [25]. Cancer and Leukemia Group B

2.1. Conventional chemotherapy
Chemotherapy remains the mainstay treatment for TNBC. These
agents are usually anthracycline, platinum, and/or taxanes. Anthracy
clines such as doxorubicin (DOX) and epirubicin (EP) have shown
enhanced response rate and survival by 22 months [9–12]. These agents
have proven to be beneficial and have shown enhanced sensitivity when
used as a single agent [10,11] as well as in neoadjuvant setting [12].
Phase III clinical trial of anthracyclines as an adjuvant agent versus CMF
(cyclophosphamide, CP; methotrexate, MTX; and 5-fluorouracil, 5-FU)
[13] demonstrates a 23% decrease in the recurrence rate. A 17% path
ological complete response (PCR) in Phase II clinical trial was observed
in a neoadjuvant setting with anthracyclines agents in combination with
others such as CP, 5-FU, and epirubicin (ER) [14]. A Phase III clinical
trial demonstrate that a 5-year disease-free survival was achieved in
71% of the TNBC patients treated thrice every week in contrast to only

Fig. 1. Schematic illustration of various treatment strategies for TNBC. Conventional strategies with chemotherapeutic agents (doxorubicin, paclitaxel, and
cisplatin), targeted strategies includes specific pathway inhibitors, immunotherapies, and nanotechnology (drug loaded nanoparticles or antibody drug conjugates).
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(CALGB) team conducted a trial on 9344 subjects, demonstrate
disease-free survival among TNBC patients treated with PTX, versus all
other subtypes of BC [26]. BC International Research Group (BCIRG)
reported a clinical trial report that indicated an advantage in the group
that was co-treated with PTX over cyclophosphamide on the TNBC
cohort [27]. Further, a non–platinum-based neoadjuvant therapy with
CP-DOX-vincristine-prednisolone shows a 15% increase in the PCR in
comparison to all the other regimen, suggesting TNBC apart BRCA
mutation subset, has greater response to taxanes in comparison to other
regimens [28].

prognostic marker [42], whereas some suggest they have a higher nu
clear grade, high lymph node metastasis, and higher mortality rate [43].
Enzalutamide is a novel targeted AR inhibitor that competitively binds
to the AR and prevents translocation to the nucleus [44]. NCT02750358
is a Phase II ongoing clinical trial for determining the compliance rate of
enzalutamide as adjuvant therapy for a 1-year dose [45]. In another
Phase II clinical trial, superior benefits are achieved with enzalutamide
indicating this may be a therapeutic option for patients. To further
evaluate the efficiency of enzalutamide with PTX a phase IIB is currently
ongoing. Bicalutamide also an AR inhibitor, has shown to have prom
ising results in a phase III clinical trial for metastatic TNBC patients [46].
The role of activation MAPK was initially investigated in vitro, which
causes loss or downregulation of various genetic and epigenetic func
tions that are associated with chemoresistance. MEK inhibitors are
known to cause efficient suppression of chemoresistance either alone or
in combination with other chemotherapeutic drugs. Significant inhibi
tory effects were seen with combination treatment of cobimetinib with
PTX [47]. Another study demonstrates, MEK inhibitor selumetinib given
in combination with either buparlisib or the platelet-derived growth
factor receptor inhibitor pazopanib, showed effective inhibition of brain
metastases in TNBC patients [48]. An ongoing clinical trial shows MEK
inhibitor trametinib in combination with gemcitabine showed complete
response in the patient with metastatic TNBC [49]. However, there have
been serious toxicities prohibiting phase II clinical study of MEK in
hibitor with mTOR or PI3K inhibitors [50,51].
CDK is responsible for hyperphosphorylation of retinoblastoma
protein (RP) and causes G1-S phase transition in the cell cycle [52]. CDK
inhibitors thus were explored as a potential target for TNBC. Palbociclib
is a selective inhibitor of CDK and was explored in clinical trials for
TNBC with positive RP expression, that demonstrated a partial response
in 50% of the patients, improving disease-free survival for 6 months or
more [53]. There are several other clinical trials conducted either alone
or in combination with other chemotherapy.

2.2. Targeted therapies
The molecular heterogeneity of TNBC [6] makes it difficult for
physicians and clinicians to have a standard care guided approach for
the treatment. Advancement in the molecular classification and genome
sequencing has led to the development of targeted therapy [6,8]. From a
variety of gene expression analysis, six main subtypes of TNBC have
been proposed, viz. basal-like 1, basal-like 2, immunomodulatory,
mesenchymal, mesenchymal stem-like, and luminal androgen receptor
(AR) [29]. Numerous clinical trials are underway to develop targeted
therapy for TNBC using inhibitors of poly ADP ribose polymerase
(PARP), phosphatidylinositol 3-kinase/Protein kinase B (PI3K/AKT),
mitogen-activated protein kinases (MAPK), and cyclin-Dependent Ki
nase (CDK).
Among these therapies, PARP-1 inhibitor(s) leads to enhanced DNA
double-strand breaks causing an increase in apoptosis [30–32]. PARP-1
inhibitor has been particularly beneficial in BRCA1 and BRCA2 mutant
cells because of their ability to sensitize cells [31,32]. Although BRCA
mutations account for only 20% of TNBC population, yet several PARP
inhibitors have gained clinical approval such as olaparib, veliparib,
niraparib, rucaparib, and talazoparib. Phase III clinical trial in TNBC
patients with BRCA mutation report that oral PARP inhibitor olaparib
increases the progression-free survival to 7 months in contrast to 4.2
months in the placebo group. US Food and Drug Administration (FDA)
approved the first PARP inhibitor (olaparib in 2018) for the treatment of
advanced-stage BRCA mutant TNBC [33]. Talazoparib treatment
confirmed that about 53% of patients achieved PCR in a phase II clinical
trial NCT02282345 [34]. A larger single-arm Phase II study
(NCT03499353) proved that talazoparib is highly effective in HER2
negative advanced BC with an overall survival of 24.3 months, in
contrast to only 6.3 months in patients receiving only chemotherapy.
This lead to the approval of the second PARP inhibitor for germline
BRCA mutation [34].
The PI3K/AKT regulates cell growth and glucose metabolism. There
are complexities associated with the activated PI3K/AKT pathway,
although activated PI3K/AKT pathway is high in TNBC [34]. Ipatasertib,
an oral AKT inhibitor is used with PTX demonstrated improved
progression-free survival from 9 months to 4.9 months in TNBC patients
(phase II NCT02162719) [35] and improvement in overall survival of
23.1 months versus 18.4 months [36]. Inhibition of epidermal growth
factor receptor (EGFR), a transmembrane tyrosine kinase receptor by
PI3K/AKT pathway has proven to be useful in the treatment of TNBC.
However, cetuximab a humanized monoclonal antibody used in com
bination with other taxanes failed to show significant improvement in
the TNBC subtype [37]. Similarly, another phase II multicenter clinical
trial by the Translational BC Research Consortium demonstrates that
cetuximab used alone or in combination with platinum agents such as
cisplatin and carboplatin, failed to show any impressive result by the
anti-EGFR antibody [38]. This is probably because only 50% of the
TNBC cases are EGFR positive [39].
AR accounts for 13–37% among TNBC patients and it is more prev
alent among older [40,41] people. However, the role of AR as a prog
nostic marker in TNBC is not clear, as there are contradictory reports
about the characteristics of AR in TNBC. It is also associated with low
nuclear grade, and low proliferative rate and is unrelated to be a

2.3. Antibody-drug conjugates
Antibody-drug conjugates (ADCs) are also considered as targeted
therapy where the toxic anticancer drug targets the cancer cells through
the specific binding of an antibody that has specificity for receptors on
the surface of the cancer cell. There have been lot of ongoing research
using ADCs for TNBC with some of them discussed below. Trophoblast
antigen 2 (Trop2) [54] is target via ADC for TNBC. IMMU-132, also
known as sacituzumab govitecan is an ADC that targets Trop2 and have
been used in combination with three PARP inhibitor; olaparib, rucaparib
and talazoparib and have shown improved overall response [55].
Another compelling ADC, glembatumumab vedotin that combines the
monomethyl auristatin E (MMAE) (a potent microtubule-disrupting
agent) shows improvement in disease-free progression in Phase I/II
clinical trial [56]. However, data suggests that a 100 mg dose caused
some toxicity of grade 3 and 4, which may limit the usage of these agents
[57]. Ladiratuzumab vedotin is another ADC explored for targeting
TNBC and is composed of a humanized IgG1, MMAE and a monoclonal
antibody for targeting oestrogen-regulated gene (LIV-1). LIV-1 is over
expressed in 90% TNBC tumors but is not significantly expressed in
normal tissues. In a phase I study with ladiratuzumab vedotin a 25%
overall response rate was achieved. Although there are toxicity issues
such as alopecia, neutropenia and peripheral neuropathy. Ongoing
studies are still conducted to evaluate the efficiency of ladiratuzumab
vedotin as monotherapy or in combination with chemotherapy for TNBC
[58].
2.4. Immunotherapy
TNBC is known to have the highest mutations among all other types
of BC. The role of tumor-infiltrating lymphocytes play a major role in
disease progression in TNBC. Thus, activation of these cytotoxic T cells
3271
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would be initiating an antitumor immune response. T cells show the
expression of immune checkpoint inhibitors: cytotoxic T-lymphocyte
antigen 4 (CTLA-4) and programmed death-1 (PD-1). PD-1 inhibitors are
the most extensively studied checkpoint and is a cell surface protein
expressed on the infiltrating tumor lymphocytes that induce inhibition
of T cells by binding to two ligands: PD-L1 and PD-L2 [59]. Researchers
are actively involved in evaluating the role of these checkpoint in
hibitors and have shown some encouraging results for the treatment of
TNBC. Among PD-1 inhibitors, pembrolizumab was evaluated as a
first-line therapy in PD-L1 positive TNBC patients. In which 87% of the
patients had received either neoadjuvant or adjuvant chemotherapy,
with overall survival outcome being 16.1 months [60]. In another phase
II trial, I-SPY 2 trial (NCT01042379), 69 HER- and 29 TNBC patients
were received either neoadjuvant PTX and/or pembrolizumab, followed
by dose-dependent doxorubicin and cyclophosphamide. The raw PCR
was improved to 71% with pembrolizumab compared to 19% in the
control arm, whereas the estimated PCR was 62% with pembrolizumab
versus 22% in the control arm [60]. The beneficial results achieved
through I-SPY 2 trial led to the phase III trial, KEYNOTE-552
(NCT03036488) and KEYNOTE-355 (NCT02819518) which are
currently ongoing. Another PD-L1 inhibitor that has achieved impress
ing outcomes among TNBC patients is, atezolizumab. Impassion130
trial, NCT02425891 which was a phase III trial, among metastatic or
advanced stage TNBC patients receiving Abraxane with/without atezo
lizumab plus placebo. A 1.4 fold improvement was achieved among
patients receiving atezolizumab, with progression-free survival of 2.5
months, versus 1.7 months who did not receive atezolizumab. Overall
survival was also improved to 9.5 months, with no significant
improvement observed among patients without atezolizumab [61].
Based on these results, the FDA accelerated the approval of atezolizu
mab with Abraxane for the treatment of metastatic TNBC patients who
are PD-L1 positive. Further ongoing phase III trial NCT03125902 is
being evaluated with patients receiving either atezolizumab and PTX
versus PTX and placebo for first-line therapy in TNBC.
Due to the heterogeneity and the inherent nature of TNBC to develop
multi drug resistance (MDR) to conventional chemotherapeutics, several
ongoing clinical trials with combination therapies or targeted therapies
or immunotherapies or ADC, are being evaluated to identify predictable
biomarkers that will improve treatment outcomes among TNBC pa
tients. Although, the paradigm is shifting and lots of attention is being
given to the development of novel and nano-based therapies for TNBC.

resulting in transport of maximal payload, improving half-life and sys
temic circulation, less immunogenic reaction, controlled drug release,
increase in drug solubility, and stability of poorly water-soluble
chemotherapeutic agents (which compromises the majority of avail
able, approved, and marketed chemotherapeutics). Alongside taking
advanatage of synergistic effects, combined therapy has been able to
deliver multiple therapeutic agents for multimodal functions, such as
imaging and/or theranostic agent [66–68]. Some of the commonly
employed nanoparticles [62] that have been explored for delivery of
therapeutics are polymeric nanoparticles, micelles, liposomes, den
drimers, nanoconjugates, albumin nanoparticles, and carbon nanotubes
(Fig. 2).
These unique nanostructures can be generated following various
synthetic methods [69,70]. Hydrothermal, sonochemical, polyol, mi
crowave synthesis, inert gas condensation, ultrasound, laser ablation,
thermal decomposition, electrochemical, gamma radiation, spark
discharge, sputtering, template synthesis, sol-gel, biological building,
co-precipitation, microemulsion process are commonly used approaches
to construct these nanostructures [69,71]. It is possible to achieve dry
nanoparticle powders or nanoparticles dispersed in liquid medium.
Researchers have employed other techniques such as polymer precipi
tation, emulsion-solvent diffusion, emulsion-reverse salting out, inter
facial condensation, polyelectrolyte complexation, ionic gelation and
many other similar techniques for drug loaded NPs [72]. The super
critical fluid technology (rapid expansion of supercritical solution, su
percritical anti solvent, aerosol solvent extraction system, solution
enhanced dispersion by supercritical fluid, and particles from
gas-saturated solutions/suspension) is highly considered to generate
pharmaceutical based particles [73,74]. This new technology overcome
the drawbacks of spray drying and milling techniques. All these systems
are further modified for delivering not only drugs but also oligonucle
otides, DNA or proteins [75].
3.1. Polymeric nanoparticles
Polymeric nanoparticles are nanosized range materials that are
synthesized using either natural or synthetic biodegradable and
biocompatible polymers. Depending on the characteristics of the poly
mer of choice, both hydrophilic and hydrophobic drugs can be encap
sulated into these nanoparticles that can be released by surface or bulk
erosion, swelling or diffusion mechanisms. Studies have shown that
polymeric nanoparticles made of poly(ε-caprolactone)-b-poly(ethyl
eneglycol)-b-poly(ε-caprolactone) encapsulating DTX successfully
improved the in vivo survival rate of mice in contrast to marketed
docetaxel formulation due to the prolonged circulation of the nano
particles for the EPR effect [76]. Similarly, poly(lactic-co-glycolic
acid)-poly(ethyleneglycol) nanoparticles were utilized to deliver
cisplatin in TNBC xenograft mouse model with significant tumor inhi
bition and prolongation of half-life, although systemic toxicities were
observed in normal organs such as kidney and liver [77].
Inadequate therapeutic dose reaching the tumors via passive tar
geting has led to the utilization of nanoparticles by decorating the sur
face with active moieties allowing longer circulation and causing higher
concentration accumulating in tumor tissues compared to normal tis
sues. For instance, a novel peptide (Gly–Ile–Arg–Leu–Arg–Gly) conju
gating onto polymeric nanoparticles containing PTX, exhibited a
significant delay in tumor growth in contrast to untargeted nano
particles [78]. A protein polymer called elastin-like polypeptides was
used to form nanoparticles that assemble into <100 nm and was surface
decorated with FK506 binding protein 12, which is a cognate receptor
for potent yet poorly soluble rapamycin (RPM). These nanoparticles
prolonged circulation time and increased the half-life by 26 folds, with
enhanced anti-tumor efficacy, and lower cytotoxicity than free drug in
TNBC xenograft mouse model [79]. Enhancer of zeste homolog 2 (EZH2)
was found to be overexpressed in TNBC and is found to be responsible
for poor overall patient survival. Delivery of siRNA via chitosan

3. Nanotechnology based therapies for TNBC
The lack of specific (ER, PR, and HER2) cellular receptors on TNBC
tumors, makes drug delivery to the tumor challenging. So researchers
are extensively focused on targeted delivery to TNBC. In this regard,
nanotechnology-based delivery systems have been beneficial to provide
significant tumor delivery by following active- and passive-targeting
mechanisms [62]. Passive targeting occurs by a phenomenon known
as the enhanced permeability and retention (EPR) effect. This phe
nomenon occurs because of the tumor vasculature that is hyper vascu
larized with enhanced vascular permeability causing fluid retention and
lack of lymphatic drainage. This results in extravasation within tumor
tissues and increased accumulation of therapeutics at the intertumoral
site, whereas they get cleared into the lymphatic system of healthy tis
sues [63]. However, achieving therapeutic concentrations inside the
tumor site is a challenge with passive targeting and, as a result of which
compromises are usually made on the biotherapeutic window of the
drug. Active targeting relies on conjugating the surface of the nano
particle to biocompatible targeting moieties such as aptamers, anti
bodies, and peptides, that have specificity to the antigens or receptors at
the tumor site [64,65]. This approach provides a myriad of advantages
over conventional therapeutic approaches, such as target specific de
livery, minimizes systemic or non-specific toxicities, increases bio
distribution and therapeutic window with intravenous administration,
3272
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Fig. 2. Graphic representation of structurally varied nanoformulations, polymer nanoparticles, polymer micelles, liposomes, dendrimers, polymer conjugates, al
bumin nanoparticles, and carbon nanotubes used in cancer therapeutics including TNBC. These nanostructures are able to accommodate small/biomacromolecular
therapeutics, contrast/imaging, and other agents that imparts therapeutic and/or theranostic properties.

nanoparticles directed to target the EZH2 in the orthotopic
MDA-MB-231 mouse model has shown to cause a significant reduction
in tumor growth [80].

initiated the fast track approval through 505(b)(2) for new drug appli
cation (NDA) regulatory pathway for Cynviloq® in the U.S [89]. Pacl
ical® developed by Oasmia Pharmaceuticals, which is composed of
XR-17, a vitamin A derivative which is made of N-(all-trans reti
noyl)-L-cysteic acid methyl ester sodium salt and N-(13-cis reti
noyl)-L-cysteic acid methyl ester sodium salt. It forms micelles of 20–60
nm which encapsulates PTX and is available as a lyophilized powder,
administered as infusion [90]. Pharmacokinetic profile of Paclical® and
Abraxane® are similar, suggesting the opportunity for approval of
Paclical in the treatment of metastatic BC [91]. Nanoxel® from Dabur
Pharma Limited (India) is available for the treatment of metastatic BC,
ovarian cancer, NSCLC, and AIDS-related Kaposi’s sarcoma in India. It is
a micellar solution of size range 80–100 nm, is composed of a
pH-sensitive copolymer of N-isopropyl acrylamide and vinylpyrrolidone
monomers which is stable at physiological pH and drug release in an
acidic environment as tumor microenvironment [92]. Ranade et al. [93]
demonstrates in phase I clinical trial the MTD to be 375 mg/m2 with a
linear pharmacokinetic behavior with grade 3 diarrhea and grade 4
neutropenia adverse effects. However, the same group conducted a
phase II trial in anthracycline failed advanced metastatic BC patients
and show though the formulation in comparison to the generic formu
lation Taxol® has improved overall response rate, being 40% and
32.3%, the higher incidence of neutropenia of 56.3% versus 50%, higher
incidence of neuropathy of 12.5% versus 6.3, respectively [92]. Tri
olimus® from Co-D Therapeutics is a polymeric micellar formulation
(30–40 nm) composed of PEG-PLA and encapsulates three drugs, PTX,
RPM (mTOR inhibitor), and tanespimycin (17-AAG, Hsp90 inhibitor)
[94]. After showing promising preclinical results in xenograft models by
the synergistic activity of the three actives, this formulation is in the
process of phase I clinical trial for breast, NSCLC, and angiosarcoma
[95]. NK105 is a micellar formulation composed of polyethylene glycol
and modified polyaspartate by esterification with 4-phenyl-1-butanol
and is about 85 nm in diameter [96]. The core encapsulates 23%
(w/w) of PTX and demonstrates good drug retention after intravenous.
administration. This formulation has MTD of about 180 mg/m2 in phase
I clinical trial with grade 3 neutropenia as the adverse dose-limiting
toxicity. Pharmacokinetic profile of this formulation in comparison to
the marketed generic formulation Taxol® has 15 folds higher AUC at the
recommended dose of 150 mg/m2. However, in phase III clinical trial
against metastatic BC enrolled patients failed to meet the primary
endpoint of the study [97].

3.2. Polymeric micelles
Polymeric micelles are developed by using hydrophilic and hydro
phobic chains of polymers, that form Van der Waals bonds to form a
hydrophobic core which usually encapsulates the drug either by phys
ical entrapment or chemical bonds. The outer shell on the other hand
being hydrophilic, aids prolong circulation and prevents rapid clearance
by the reticuloendothelial system (RES) [81]. A block copolymer of poly
(ethylene glycol) (PEG) and poly(glutamic acid) conjugated to the active
metabolite of topoisomerase I inhibitor irinotecan (SN-38) forms ~ 20
nm spherical polymeric micelles. Significant tumor inhibition in an
orthotopic mouse model has suggested this could be a promising
candidate and is in Phase II clinical trial for treatment in TNBC patients
[82]. Active targeting by polymeric micelles using D-tocopheryl PEG
succinate polymer, encapsulating DTX conjugated to cetuximab, that
specifically targets EGFR on the TNBC tumors by 205.6 and 223.8 folds
in contrast to Taxotere® (marketed formulation of docetaxel) [83].
Various polymer micelle-based PTX formulations exist for clinical
use. Genexol-PM® (Cynviloq™) was developed by Samyang Bio
pharmaceuticals Corporation (South Korea) for the treatment of several
types of cancer, such as breast, ovarian cancer, and NSCLC. It is made up
of monomethoxy-PEG-b-poly(D,L-lactide) diblock copolymer that entraps
PTX in polymeric micelles (20–50 nm) with a drug loading capacity of
16.7% w/w. The absence of albumin reduces the risk of microbial
contamination in comparison to Abraxane. A phase III clinical trial
(NCT00876486) of the formulation in contrast to the Abraxane in
metastatic BC, shows enhanced efficacy and reduced toxicity issues
[84]. Other clinical trials demonstrate that the MTD of this formulation
was lowered to 180 mg/m2 than that of Abraxane®, although both the
regimens showed a similar incidence of neutropenia and less severe
non-hemotoxicity [85,86]. Although, the higher-dose regimen of 390
mg/m2 has a higher incidence of neutropenia and neuropathy [87]. In
phase II clinical trial at a dosing regimen of 300 mg/m2 in metastatic BC
patients, 58.5% of them demonstrate response rates. However, the
response rate of Taxol® was similar but conducted in a much larger
group. Also, greater incidence of neutropenia (68.3%), neuropathy
(51.2%), and hypersensitive reaction (19.5%) was observed [88].
Overall, Genexol-PM® showed a similar response to Taxol®, which
3273
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3.3. Liposomes

This modification allows a high drug loading capability of doxorubicin
via this approach exhibiting superior tumor growth inhibition and no
systemic toxicity in comparison to the free drug in orthotopic TNBC
murine model [111]. Similarly, liposome vesicles can efficiently
encapsulate arsenic trioxide (which has dose-limiting toxicity and rapid
clearance) resulted in enhanced antitumor efficacy than the parent drug
in an orthotopic murine model with pharmacokinetic parameters and
efficacy profile [111]. PEGylated liposomal formulation of DOX and
gemcitabine showed remarkable responses in TNBC patients, however
adverse effects such as metastasis to the skin have limited its use [112].
In an attempt of active targeting, integrin α3 that is overexpressed in
TNBC models and is known to cause tumor angiogenesis, proliferation,
therapeutic resistance, and poor prognosis, is attached to the surface of
PEG-PCL based liposomes. The authors attach a cyclic octapeptide LXY
(Cys–Asp–Gly–Phe(3,5-DiF)–Gly–Hyp–Asn–Cys) and achieve enhanced
accumulation of co-administered drugs (DOX and RPM) at the tumor
site, resulting in improved antitumor efficacy in in vivo TNBC model
[113]. Active targeting of eEF-2K which has shown to cause tumori
genesis and is associated with a poor prognosis in TNBC, by neutral
liposomal siRNA formulation leads to a significant inhibition in tumor
growth in orthotopic TNBC mouse model [114]. EndoTAG-1 is a
PTX-loaded liposome formulation for targeting the activated tumor
endothelial cells has entered Phase III clinical trial after showing
promising results in contrast to plain drug in TNBC patients [105].
Paclitaxel injection concentrate for nanodispersion (PICN) is a
nanoparticle-based formulation composed of polymer and lipid,
polyvinyl-pyrrolidone, cholesteryl sulfate, and caprylic acid-forming
nanoparticle of 100–110 nm, developed by Sun Pharma and approved
in India for the treatment of metastatic BC. This formulation is castor oiland albumin-free formulation of paclitaxel and alternative for Taxol®
and Abraxane®. Jain et al. evaluated the efficacy of this formulation in
comparison to Abraxane in phase II/III clinical study and demonstrate
similar efficacy and tolerability profile at MTD of 260 mg/m2. Although
the incidence of most common side effects such as neutropenia, pe
ripheral neuropathy, and leukopenia was the least at MTD 260 mg/m2
versus PICN 295 mg/m2 and Abraxane 260 mg/m2, yet there was no
statistically significant difference between them [115]. In U.S. PICN is in
phase III clinical trial for the treatment of biliary tract carcinoma
(NCT02597465) [116] and just finished phase I trial when administered
alone or in combination with carboplatin (NCT01304303), the results
are yet to be disclosed [117].

Liposomes are composed utilizing the lipid bilayer characteristics,
which allows the formation of spherical vesicles as large as 100–400 nm,
enclosing an aqueous core. The lipid bilayer being amphiphilic allows
the interaction of the hydrophilic surface of the lipid with the central
aqueous core-forming lipid spheres, whereas the hydrophobic region
can be modified as per drug delivery needs. The ability of drug loading
both in the aqueous core or lipid bilayer and the possibility of active and
passive targeting makes liposomes an attractive alternative for re
searchers. A liposomal PTX-formulation called Lipusu® is communal
ized by LuyePharma Group in China consists of lyophilized powder of
PTX solubilized in liposomes made of lecithin and cholesterol in a ratio
of 87:13 w/w % and is 400 nm in diameter. It is approved in China as
first-line chemotherapy for ovarian cancer, first-line therapy for NSCLC
patients not suitable for radiotherapy or surgery, and for BC. Wang et al.
[98] investigates the anaphylactic effect of the formulation in contrast to
Taxol® and showed adverse responses such as piloerection, anhelation,
and syncope, which were not seen in animals treated with Lipusu®.
Lipusu® showed some milder hypersensitivity reactions [98]. There are
several ongoing clinical trials (NCT02142790 for metastatic BC and
NCT02142010 for Lipusu with cisplatin in BC) [99] to evaluate the ef
ficacy in comparison to other standard regimen. Another liposomal PTX
formulation (LEP-ETU®) developed by NeoPharm cardiolipin, choles
terol, and D-α-tocopheryl acid succinate (in the molar ratio 5:5:90) and
are about 150 nm in diameter. Phase I clinical trial to study the
dose-limiting toxicities at 325 mg/m2 associated with the treatment of
LEP-ETU® shows peripheral neuropathy, myelosuppression, and even
neurotoxicity [100]. Slingerland et al. demonstrate that the pharmaco
kinetic profile (AUC and Cmax) of LEP-ETU® were similar to Taxol®
[101]. A phase II clinical trial has conducted to determine the safety and
efficacy of LEP-ETU® in thirty-five subjects show sensory poly
neuropathy (3%) and neutropenia (6%). Other than that no significant
reactions were observed [102].
EndoTAG-1® is a PTX formulation developed by MediGene and later
taken over by SynCore Biotechnology. It is comprised of liposomes
composed of phospholipid DOTAP and neutral phospholipid DOPC in a
53:47 M ratio and are about 200 nm in diameter and positive zeta po
tential of 25–100 mV in a 0.05 mM KCl solution at pH 7.5 [103]. The
positively charged liposomes promote the PTX uptake into the tumor
endothelial cells. As a result of which combining antivascular effects
with conventional chemotherapy may result in increased permeability
within the tumors [104]. However, preclinical and clinical trial con
ducted on other types of cancer such as adenocarcinoma, pancreatic
cancer is shown to cause neutropenia and thrombocytopenia. Efficacy in
TNBC was evaluated by Awada and coworkers [105], showing results
from a phase II clinical trial comparing the safety and efficacy of
EndoTAG-1® with Taxol® in 140 patients, receiving either weekly
EndoTAG-1® with Taxol® or EndoTAG-1® (twice a week) or weekly
Taxol®. However, there was no significant improvement in the overall
survival between the treatment groups (13.0, 11.9, and 13.1 months,
respectively). Other adverse effects include pyrexia and chills and about
17.8% discontinued the therapy due to unbearable adverse events.
Ongoing clinical trials evaluating EndoTAG-1® for treatment of TNBC
(NCT01537536 and NCT00448305) [106,107]. CAR, a homing peptide
modified liposomal with fasudil or fasudil-DETA NONOate combination,
can efficiently concentrate in the lungs [108,109] for the treatment of
pulmonary arterial hypertension. Additionally, this construct and
methodology can also be applied with other cancer drugs for the treat
ment of TNBC that are metastasized to the lungs.
Researchers have utilized lipid-based nanocapsules to entrap lipo
philic drug ferrocenyl tamoxifen derivative FcOHTAM and demon
strated improved antitumor effects in TNBC xenograft model that is
resistant to tamoxifen treatment [110]. Lipid-based nanoparticles were
constructed from chemically modified cholesterol-terminated poly
(acrylic acid) and cross-linked with diamine linkers for active targeting.

3.4. Dendrimers
Dendrimers are repeating branched monomers arising radially from
the central core, formed by the polymerization reaction. These den
drimers are usually 10–100 nm in size with an amphiphilic nature
having a hydrophobic core and a hydrophilic outer periphery [118]. Due
to the polyvalent nature of dendrimers like micelles, gene delivery,
active targeting can also be possible by conjugating ligands or imaging
compounds. Wang et al. [119] utilizes a fourth-generation poly(ami
doamine) dendrimers conjugated to antisense oligodeoxynucleotides for
targeting the vascular endothelial growth factor expressed in TNBC
cells. The authors report an increased accumulation of dendrimers in
TNBC-xenograft mouse model with significant reduction in expression
of vascular endothelial growth factor, in comparison to unconjugated
nanoparticles. Gene delivery using dendrimers was further displayed, in
which a third-generation poly(amidoamine) dendrimer was used to
deliver YTZ3-15 that can knockdown the TWIST1 transcription factor
and is associated with aggressive behavior, metastasis, and cellular
migration through an epithelial-mesenchymal transition in TNBC cells
[120].
3.5. Nanoconjugates
Nanoconjugates are nanoplatforms that are covalent complexes that
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can bind to multifunctional groups, providing an opportunity to a con
jugate protein(s) or peptide(s) of interest such that cell- or tissue-specific
targeting can be achieved [121]. Mittapalli et al. [122] construct an
ultra-small hyaluronic acid-PTX nanoconjugates of 2–3 nm that can
target CD44 receptor located on the surface of metastatic cancer. CD44
receptor-mediated endocytosis results in 10 folds increase in cellular
uptake and significant improvement in overall survival of animals in a
TNBC mouse model of the brain metastasized in contrast to the plain
drug. The multifunctionality of nanoconjugates was further explored
and demonstrated poly (β-L-malic acid) nanoplatforms was formed by
conjugation of a 2C5 monoclonal antibody and for active targeting:
anti-mouse transferrin receptor (TfR) antibody and oligonucleotides
(MASONs). This approach allows active targeting of EGFR-positive
TNBC cells, resulting in significant tumor inhibition via the EGFR
pathway thus controlling tumor progression [123]. A similar nano
conjugate was constructed utilizing such nanoplatforms and produces
significant tumor inhibition with no systemic toxicity in TNBC xenograft
mice. This strategy was employed for active targeting of three oligo
nucleotides, leading to a significant arrest of EGFR and laminin-411
which are known to cause tumor growth and angiogenesis [124,125].
A folate-drug nanoconjugate of folic acid and tubulysin B hydrazide
entered into clinical trial for many types of aggressive cancer including
TNBC subtype [126]. HPMA copolymer–PTX is the first polymer-drug
conjugate of PTX, developed by Pharmacia Corporation, conjugating
PTX to HPMA by a tetrapeptidil linker of glycylphenylalanylleucylgly
cine. Although the formulation has a good aqueous solubility and about
5% w/w drug loading capacity, it failed to have any difference in
pharmacokinetic behavior, illustrating that the conjugation did not have
any significant impact on the drug behavior, though a partial response
was observed in one of the twelve patients with advanced BC. However,
clinical studies in phase I was discontinued earlier due to severe
neurotoxicity observed [127]. Opaxio™ is a polymer drug conjugate of
PTX conjugated to the poly(L-glutamic acid) at the 2′ -hydroxyl position
of the drug by an ester linkage. It is available as a lyophilized powder
and has shown beneficial results in preclinical studies. In ovarian tu
mors, uptake of Opaxio™ was about 5-fold higher than Taxol® with
prolonged circulation time [128]. After promising preclinical results,
pharmacokinetic profiling of this compound in comparison to the orig
inal drug shows prolonged half-life and low renal clearance, however,
the achieved Cmax was 3 times lower than Taxol® [129]. Also, similar
dose-limiting toxicity such as neuropathy and neutropenia similar to
taxane(s) was observed. CT-2103 completed phase II trial for metastatic
BC [130] and is also being evaluated in combination with carboplatin
versus PTX and carboplatin in NSCLC patients [131]. ANG 1005 is a drug
peptide conjugate of angiopep-2 and PTX that binds to the low-density
lipoprotein receptor-related protein (LRP)-1 which facilities movement
across the blood-brain barrier (BBB), as LRP-1 is highly overexpressed in
BBB. In a preclinical model, ANG 1005 has shown therapeutic efficacy
which has progressed its application in a clinical trial. In phase II trial
among metastatic BC patients promising results have been achieved
with the application of ANG1005 to treat peripheral metastatic BC and
brain metastasis [132]. It is now in phase III clinical trial
(NCT03613181) [133].

distribution are significantly higher than the traditional formulation. It
is well distributed and binds to the tissue and extravascular proteins
[135]. Preclinical studies demonstrate an improvement in efficacy, in
contrast to Taxol® and 33% higher tumor accumulation and less toxicity
[136]. Advantages such as the ease of administration, reduction in some
of the adverse effects like hypersensitivity reactions, better overall
response, and survival were achieved. Although, Abraxane shows a
reduced risk of neutropenia yet increased incidence of neurotoxicity is
overserved in combination with gemcitabine in pancreatic cancer [137].
Additionally, a randomized clinical trial CALGB 40502, suggests that
toxicity profile for both the treatment groups receiving either PTX or
nab-PTX weekly has no improvement, in fact, more neuropathy and
myelosuppression were observed with nab-PTX [138].
Clinical trials on BC patients receiving weekly Abraxane shows it is
well-tolerated and has higher antitumoral activity in contrast to PTX.
However, grade 4 neutropenia and grade 3 peripheral neuropathy were
observed as dose-limiting toxicities [139,140]. Gradishar et al. [141]
conducted a phase III clinical trial on metastatic BC patients with
Abraxane showing a significantly higher response rate of 33% versus
19% improvement with Taxol®. However, no significant difference in
overall survival, which is considered one of the most important pa
rameters to evaluate clinical efficacy. Another phase III trial treated with
Abraxane® (125 mg/m2) or Taxol® (80 mg/m2) each given weekly,
followed by epirubicin/cyclophosphamide, shows significant higher
PCR especially in the TNBC cohort in comparison to Taxol® (38% vs
29%). However, Abraxane® was associated with significantly greater
toxicities such as peripheral sensory neuropathy compared with Taxol®
(10% vs 3%) [142].
3.7. Carbon nanotubes
Carbon tubes are cylindrical structures made from benzene rings and
are insoluble in any solvent and thus can be modified chemically to
become water soluble or can be functionalized with multiple groups.
This unique nanoneedle shaped and the monolithic structure allows
passive diffusion to the lipid layer can be multi-functionalized and can
be considered an important drug carrier for cancer therapeutics [143,
144]. Carbon nanotubes could be single-walled (around 1–2 nm, one
layer) or multi-walled (around 5–100 nm, multiple layers), depending
upon the number of cylindrical layers. Chemical modification of
single-walled carbon nanotubes via an ester bond yielded a branched
polyethylene glycol chain to which PTX was conjugated to the
water-soluble carbon nanotubes. This conjugate exhibited 10 times
higher tumor uptake than the conventional Taxol® and little toxicity in
murine 4T1 breast TNBC model. The improved circulation is probably
because of the PEGylation that resulted in more suppression in tumor
growth due to the enhanced permeation and retention [145]. Another
interesting application of these carbon nanotubes is based on photo
thermal-induced ablation, where nanotubes promote cell membrane
permeabilization and necrosis, eliminating both tumor mass and BC
stem cells, suggesting this could be an effective treatment option for
tumor resistant and preventing recurrence [146].
4. Biological and biomimetic nanomedicine

3.6. Albumin-based nanoparticles

Active targeting by attaching ligands on nanoparticles enables to
recognize and bind to receptors on target cancer cells. Such techniques
were reported conjugating the nano-carrier systems to biomolecules
including small molecules, peptides, aptamers, and antibodies [147,
148]. Biological cells such as lymphocytes, macrophages, exosomes,
erythrocytes, and platelets are used as whole-cell carriers to depot the
free drug(s) or drug-loaded nanoparticles for a better tumor targeting
and causing detrimental effects on the cancerous cells (Fig. 3). Fig. 3
depicts cell and cell-derived drug loaded delivery system efficiently
deliver therapeutic load to the tumor cells. In the case of whole
cell-mediated drug delivery, the activated cells or natural cells often

The disadvantages associated with Taxol® caused another nano
technology based PTX formulations to be marketed by Abraxis/Celgene
with the tradename “Abraxane”. It is a solvent-free colloidal suspension
that is lyophilized, including six or seven PTX molecules non-covalently
bonded to form aggregates of 4–14 nm which further aggregates to form
130 nm in diameter. It was initially approved by FDA in 2005 for met
astatic BC but has eventually been approved for treating NSCLC, meta
static adenocarcinoma and pancreatic cancer, either as a single agent or
used in combination with other first-line treatment [134]. The phar
macokinetic profile of Abraxane suggests that clearance and volume of
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Fig. 3. Schematic representation of possible delivery options of therapeutic agents via whole cell recruitment at the tumor sites. Improved interaction, circulation,
penetration, and recruitment of cells/cellular vehicles in tumors.

recruited at the site of the injury/tumor, express receptors on their
surfaces, that has affinity for ligands present on the tumor. This process
causes receptor-ligand interactions that aid in the uptake of the drug
loaded delivery system by receptor-mediated endocytosis. On the other
hand, the cell membrane-mediated drug delivery, for example, neutro
phils are recruited readily at the tumor site as an inflammatory stimulus
and permeates the endothelium near the tumor site naturally by a
multistep process: circulation, tethering, rolling, adhesion, and trans
migration [149] into the circulation, finally infiltrating the tumor cells
causing activation due to the concentrated cytokines environment. This
can cause binding of the adhesions molecules, present on the surface of
the tumors to undergo binding with the receptors on the surface of the
cell-derived delivery systems. The upcoming sections focus on cells as
therapeutic carriers and biomimetic (cell membrane clocked) nano
particles for tumor directed delivery applications.

and provide numerous advantages such as long circulation time, abun
dant surface ligands, and flexible morphology. RBCs are the most
abundant cells in the blood (a quarter of the total volume) readily
transporting oxygen and carbon dioxide throughout the body. These
biconcave discoid cells (diameter, ~7 μm) have high drug loading ca
pacity. Due to their extremely high half-life (over 100 days), it is highly
distinguished from macromolecular structure-based drug delivery sys
tems. The presence of carbohydrates, proteins, and phospholipids on the
outer member layer provides stability and deformability allowing to
target even extremely small vascular structures [152–154]. The eryth
rocyte membrane undergoes reversible changes between expanded and
tight network structural integrity and aids in the process of evading
intravascular hemolysis [155].
This delivery system involves the controlled opening of the RBC
membrane, the encapsulation of the nano-carrier loaded anti-cancer
drugs, and the subsequent resealing of the outer membrane. For
example, it encapsulates anti-cancer drugs such as daunorubicin for
leukemia treatment, 5-fluorouracil (methotrexate) [156], and l-Aspar
aginase (l-ASNase) [157]. Erythrocytes encapsulate and protect
l-ASNase from degradation, exhibits a longer half-life, increasing the
efficiency by ten-fold, and reduce the severity of side effects. In another
study, asparaginase-loaded RBCs serve as ‘bio-reactors’ to deplete
asparagine, an amino acid required for cancer cell growth, from the
blood with a tendency of low coagulation disorders and minimum
allergic reactions [158,159]. A MTX-loaded erythrocyte treatment
approach can increase the average survival time of mice bearing hepa
toma ascites tumors by 28.5–42.8% than native MTX [159]. Magnetic
targeting using an external magnetic field was applied to DOX-loaded
RBCs which are bound to iron-oxide nanoparticles pre-coated with a
photosensitizer in the chemotherapy of cancer [160]. The modification
of the pharmacokinetic and pharmacodynamics parameters of the drug
by carrier erythrocytes maintains a relatively inert intracellular envi
ronment, decreased fluctuations in concentration, reduces drug side
effects. Thus, the molecular mechanisms of erythrocytes make them
perfect candidates as carriers of convention and new anti-cancer drugs
[155,161].

4.1. Hematopoietic stem cells as carrier for targeted delivery
The remarkable characteristics of hematopoietic stem cells give rise
to other blood cells. It makes them an appropriate fit for an efficient drug
delivery system in nanomedicine. These blood cells can be broadly
divided into three main categories: erythrocytes or red blood cells
(RBCs), leukocytes (WBCs), and thrombocytes (platelets). These hemo
cytes play an important role in the defense mechanism of the body
against a wide range of pathogens and foreign particles. The biological
drug delivery system (using blood cells as drug carriers) ensures the
biocompatibility and biodegradability of the nanoparticle-loaded cell
carriers. The biochemical characteristics favor the non-immunogenicity
of blood cells guaranteeing successful drug delivery at target sites [150].
Thus, blood cells serve as the natural biological carriers that can bypass
the immune surveillance and efficiently deliver the drugs to target cells.
Some of the hematopoietic stem cells based nanocarriers that have
shown clinical potential in various cancer model has been summarized
in Table 1, with closer attention given to BC and their associated met
astatic regions [151].
4.1.1. Erythrocytes
Erythrocytes or RBCs are the ideal biological carriers for nano
medicine that can operate without inducing immunological response

4.1.2. Leukocytes
White blood cells (WBCs) or leukocytes are an integral part of the
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Table 1
Summary of various hematopoietic cells based nanocarriers for breast cancer treatment.
Cell type

Nanoparticle Core

Intended use

Targeted cancer type and benefits achieved

Lymphocytes
membrane
[236]
Monocytes [132]

Membrane coated on PLGA nanoparticles, low-dose irradiation.

Subcutaneous model
using: MKN45 cells.

pH-responsive amphiphilic copolymer, polyethylene glycol-block-poly
[(1,4-butanediol)-diacrylate-ß-N,N-diisopropylethyl-enediamine]
(PDB) and phagocyting this in Ly6Chi monocyte isolated from
peripheral blood.

Metastatic 4T1 BC.

Platelet
membrane
[237]

A synthetic peptide with dendritic disulfide conjugate of PTX coupled
with PEG via click reaction, to yield a redox-responsive micelle that
could capture internally activated platelets

Xenograft TNBC
tumors: MDA-MB-231
cells.

Platelet
membrane
[238]

Nanogel with TNF- α, RGD peptide (Nanoparticle 1). Dextran
nanoparticles with coated with platelet membrane with PTX
(Nanoparticle 2)

TNBC tumor using
MDA-MB-231 cells.

RBC membrane
[214]

Thermo-responsive hybrid nanoparticle composed of poly
(caprolactone)-ester endcap polymer (PCL),
dipalmitoylphosphatidylcholine (DPPC) poloxamer 188 and
membrane coating.

4T1 orthotropic tumor
mimicking metastasis
BC.

RBC membrane
[239]

PCL, poloxamer 188, co-administrated with the tumor penetrating
peptide, iRGD and membrane coating.

Metastatic 4T1 breast
tumor model.

RBC membrane
[240]

Ferric oxide (Fe3O4) and O-carboxymethyl chitosan (CMC)
nanoparticles co-encapsulated PTX and doxorubicin with Arg-Gly-Asp
(RGD) and membrane coating.

Subcutaneous xenograft
model of lung
carcinoma.

RBC membrane
[241]

DSPE-PEG-MAL coupled with tumor-penetrating bispecific
recombinant protein (anti-EGFR-iRGD) with RBC membrane coating.

Subcutaneous tumors of
gastric cancer cells:
MKN45.

RBC membrane
[236]

RBC membrane coated nanoparticles.

Mammalian intestinal
mucosal cells (MDCKMDR1)

Macrophage
membrane
[241]

pH sensitive polymer cationic 2- aminoethyldiisopropyl with IGF1R
targeting peptide, after PEGylation and macrophage membrane.

Orthotopic BC: MDAMB-231 cells.

Neutrophil [242]

CXCL1 chemokine laden thermosensitive hydrogel of PLGA-PEG-PLGA
nanoparticles, encapsulated by the endogenous neutrophils.

B16F10 murine
melanoma cells.

Nanoparticles caused 56.68% tumor inhibition, liver
accumulation in 96 h while LDI caused more tumor
accumulation with ~89% tumor inhibition.
2 folds increase in tumor accumulation was observed
with the monocyte loaded nanoparticles, with relatively
less nonspecific uptake in lung and liver, compared to
blank nanoparticles (no monocytes). Also, highest AUC
was observed 7.20-folds higher than PTX, with highest
tumor suppression of 96.8% over only 50.4% inhibition
was attained with nanoparticles (without monocytes).
Also, lung metastasis decreased by 99.2% with these
nanoparticles, over 50% decrease with non-monocytes
nanoparticles.
The micelles were recruited to the surface of the activated
platelets, due to overexpression of P-selectin on the
platelets and adhere to it.
Relative to PTX these targeted micelle exhibits enhanced
targeting to the primary TNBC tumors as well as lung and
liver metastasis. This is due to the interaction between
activated platelets and ICAM overexpressed at the
metastatic sites, by tumor cell receptor-targeting
strategies.
Nanoparticle1 induces tumor vascular inflammation and
RGD peptide caused significant accumulation in the
tumor by 5 folds, relative to nanoparticles without RGD.
Whereas nanoparticle2 cause greater tumor
accumulation by 5 folds relative to the nanoparticles
without coating.
A 12.3, 2.6- and 3-folds increase of fluorescent dye (DiR)
at the tumors, liver and lung metastasized sites,
respectively in comparison to free DiR. 69.2% and 12.6%
tumor inhibition were achieved by the nanoparticles, PTX
respectively, in comparison to control. Also, 98.6% lung
metastasis was achieved.
The half time of the cell membrane nanoparticles was
32.8 h (5.8 and 16.9 folds higher than that of polymeric
nanoparticles and Taxol, respectively). These
nanoparticles in combination with iRGD yield 2.89, 3.02
folds higher tumor fluorescence uptake, 90% tumor
growth inhibition and 94.8% lung metastasis were
achieved. All comparisons were with uncoated
nanoparticles with iRGD and cell membrane
nanoparticles (without iRGD).
Synergistic effect of RBC membrane magnetic
nanoparticles and RGD ligand, on the application of
magnetic field, increased fluorescent uptake at the
excised tumors by ~17 times and significant tumor
reduction in contrast to naked nanoparticles (without
membrane coating and RGD).
RBC membrane coating prolonged nanoparticle
circulation in the tumors from 2 to 48 h. The synergistic
effect of anti-EGFR-iRGD along with membrane coated
nanoparticles caused tumor inhibition by 61% in contrast
to only 21% inhibition with the PTX, relative to the
control.
Permeability was enhanced by 3.5-& 16.2 folds than free
PTX in MDCK-MDR1 cell monolayers and intestinal
mucosa, respectively. The presence of the RBC membrane
prolonged the circulation time by increasing the mean
residence time of the nanoparticles by 1.81 folds, AUC by
14.2 folds and Cmax by 6 folds, relative to free PTX.
Significantly tumor accumulation and towards the center
of the tumor was achieved, relative to group without the
non-pH sensitive polymer and without macrophage
coating, due to membrane coated tumor homing effect
and pH-sensitive drug release by the polymer. The
peptide also enhanced the fluorescence intensity due to
IGF1R mediated uptake pathway.
Neutrophils sequester the nanoparticles and in 8 h shows
82.2% uptake implying viability of neutrophils were not
affected by the PTX loaded nanoparticles. Fluorescent dye
(DiD)increased significantly at the tumor site with CXCL1
from 1 to 8 h, unlike without the CXCL1 group, suggesting
the presence of the chemokine was primarily causing
(continued on next page)
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Table 1 (continued )
Cell type

Nanoparticle Core

Intended use

Neutrophil [243]

Cationic liposomes made of 1,5-dioctadecyl-N-histidyl-L-glutamate
(HG2C18), internalized in mouse bone marrow derived neutrophils.

G422 glioblastoma
cells.

Neutrophil [244]

Commercially available PTX formulation: Abraxane dispersed within
human NEs in combination with radiotherapy by 5-Gy.

Gastric cancer: SNU719
tumor-bearing mice.

Targeted cancer type and benefits achieved
recruitment of the neutrophil loaded nanoparticles.
Synergistic effect of CXCL1 and neutrophil loaded
nanoparticles caused the most tumor inhibition of
67.28%, 2.13 folds higher without the CXCL1 group
(46.95%).
Highest fluorescent intensity of DiR dye was observed
with neutrophil nanoparticles in the tumor region of the
brain collected from surgically treated glioma tumors.
The nanoparticles migrated to the infiltrating glioma cells
GFP-G422 cells, up to 96 h, suggesting enhanced
targeting due to neutrophil which causes inflammatory
response after surgery. AUCbrain was the highest
suggesting highest targeting efficiency due to
neutrophils.
Tumor reduction was maximum when radiotherapy and
neutrophil nanoparticles were combined. The radiation
disrupts the tumor and allows the neutrophils to be
homed at the tumor site, due to the release of
inflammatory cytokines. Radiation therapy with only
neutrophil (no nanoparticle) did not produce any
significant anti-tumor effect.

infiltration of neutrophils into tumor sites markedly reducing tumor
growth and thus emerging as a novel strategy for immunotherapy in
cancer treatment [173]. Neutrophils have been heavily employed as
immune cell carriers for delivering nanoparticles to inflammation sites.
For example, piceatannol-loaded and TCPA-1/cefoperazone acid-loaded
albumin nanoparticles with neutrophils as delivery vehicles are used as
treatment approaches for acute lung injury and pyropheophorbide-a
loaded albumin nanoparticles are targeted against melanoma [165].
Therefore, neutrophil-mediated delivery of nanotherapeutics has
immense potential to dramatically increase target specificity, thera
peutic efficacy, and provide a translational effect. Their intrinsic prop
erties of transmigration, ability to infiltrate in huge numbers in response
to inflammation, and their first responder nature makes them appro
priate biological carriers to deliver nanotherapeutics [165].

innate immune system of the body in response to pathogen invasion.
When tissue damage, bacterial, and viral infections occur, leukocytes are
deployed in circulation to combat those changes. Therefore, inflamma
tion can be defined as a defense mechanism of the body to fight foreign
invaders (physical, chemical, antigens) and maintain homeostasis
[162]. Owing to their aiming movement and transmigration ability,
leukocytes are specifically targeted to deliver nanotherapeutics into
diseased tissues. The pathogenesis of most types of cancers is in corre
lation to uncontrolled inflammation. Thus, hijacking leukocytes and
deploying them as delivery vehicles to transport anti-cancer therapeu
tics across blood vessel barriers directly to the tumor microenvironment
are explored [163–165].
4.1.3. Neutrophils
Neutrophils are first-line defenders reaching at the inflammatory site
(s) migrating across the endothelial layer (neutrophil transmigration) to
fight pathogens and initiate a phase of repair. They are the most abun
dant white blood cells (50–70%) in humans and are associated with
tumor progression as well as tumor inhibition process. The neutrophils
that infiltrate tumor sites are called tumor-associated neutrophils
(TANs) [165,166]. The recruitment of TANs into tumor environment is
mediated by their surface protein composition and chemokine activity.
TANs are classified as Pro-tumorigenic (N2, produced in the tumor
microenvironment) and anti-tumorigenic (N1, ability to kill tumor cells)
which are phenotypically distinct from normal circulating neutrophils.
Targeting these neutrophils would allow better specificity and enhanced
therapeutic efficacy of anti-cancer nanotherapeutics [167,168]. Studies
have shown that inhibition of BM and ECM breakdowns by TANs
derived NE and MMP-9 can dramatically reduce tumor angiogenesis and
lung adenocarcinoma in a murine model [169]. In another study, the
successful downregulation of a murine model tumor ICAM-1 expression
via shRNA reduced colorectal adenocarcinoma by 45%. In cancer
treatments, where surgical resection has negative outcomes, anti-TAN
therapy serves a potential approach with higher disease-free survival
rates [170,171]. In a recent study, Chu et al. [172] demonstrated gold
nanorods (GNRs) linked with anti-CD11b Abs were able to exponentially
decrease tumor growth and increased survival rates in a lung carcinoma
model of mice. Photothermal therapy was undertaken as the therapeutic
method because GNRs can absorb infrared light to generate local heat to
destroy the tumor [172]. In one of their previous studies, they combined
TA99 monoclonal antibodies and albumin nanoparticles to treat mela
noma in a mouse model. This was achieved through the mechanism of
antibody-dependent cellular cytotoxicity, wherein the albumin NPs
were loaded with photodynamic therapy agents which activated the

4.1.4. Monocytes/macrophages
Monocytes are an integral part of immune-oncology with the unique
characteristic to be able to differentiate into tissue macrophage, known
as tumor-associated macrophages (TAMs), after crossing the endothelial
barrier. The ability of TAMs to reach the hypoxic areas of the tumor
microenvironment makes them excellent targets for a biomimetic based
delivery system. TAMs constitute 70% of the cell mass in breast carci
noma and can be classified into M1 and M2 types. M2-like macrophages
are responsible for tumor growth and progression whereas M1 pheno
type is associated with killing tumor cells. Owing to their innate
phagocytotic capability, monocytes can be loaded with a variety of
nanotherapeutics and serve as “Trojan Horse” delivery vehicles reaching
otherwise inaccessible tumor regions. Once these cells reach the tumor
sites, they differentiate into macrophages and their nanoparticle-based
therapeutic function could be initiated by near-infrared illumination,
henceforth destroying the TAMs associated with tumor metastasis [165,
174–177]. In a recent study, Choi et al. [178] demonstrated that the
tumor’s natural recruitment of monocytes may be exploited for
nanoparticle-based drug delivery and therapeutics. To avoid any harm
to surrounding cellular entities of the host, the drug was loaded in Au
nanoshells, nanoparticles consisting of a silica core surrounded by a thin
Au shell. Human breast tumor spheroids (T47D) were utilized as a model
to examine the therapeutic efficacy and cellular uptake of the Au
nanoshells. They successfully demonstrated the potential of monocytes
as delivery vehicles into hypoxic tumors and established a foundation
for a novel drug delivery system [178].
Poor efficiency of conventional drug delivery systems into the sites of
metastases leads to high mortality rates of BC. In a recent anti-metastasis
therapy study, He et al. [179] demonstrated that loading
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legumain-activated nanoparticles into inflammatory monocytes can
actively target lung metastases of BC and inhibit tumor progression. The
self-assembled poly(styrene-co-maleic anhydride) nanoparticles were
conjugated with a legumain-sensitive peptide and loaded into Ly6c +
inflammatory monocytes (M-SMNs). In this biomimetic delivery system,
the SMNs would remain inactive until they come in contact with the
metastatic niche. This prevents early drug release and ensures the living
state of monocytes which is required for the efficient anti-metastatic
effect. Upon reaching the tumor microenvironment, the monocytes
differentiate into macrophages to release the anti-cancer drug as free
drug molecules by destroying the macrophages. The study shows plau
sible evidence of inhibition of the proliferation, migration, and invasion
activities of metastatic 4T1 TNBC cells [179]. In another study, a mouse
macrophage-like cell line was used to demonstrate the anti-cancer effi
cacy of lung metastasis of BC (4T1 cells). A mouse macrophage-like cell
line (RAW 264.7) with similar functions to primary macrophage cells
were used as delivery vehicles and loaded with DOX to serve as an
anti-cancer biomimetic delivery system. The DOX loaded macrophage
system showed tumor suppression, metastasis inhibition, with an
increased life span of the host and reduced toxicity to other healthy
tissues and organs as compared to their control groups. Thus, DOX
encapsulating macrophages proved to be an efficient delivery system
into tumor sites and showed an enhanced therapeutic effect by inhibit
ing tumor growth to a great extent [180]. Exploiting autologous mac
rophages (MΦ) for anti-cancer therapy has been developed in the late
20th century and it still has unexplored areas to venture upon. Tumors,
however, promote normal MΦ functions of tissue repair, resulting in
tumor growth, over inflammatory responses. In the tumor microenvi
ronment, the replacement of MΦ with genetically engineered monocytes
or drug-loaded monocytes can be potential delivery vehicles for nano
therapeutics [181–183]. The encapsulation of drugs in MΦ has an added
advantage of an extended half-life, protected from clearance by the
endogenous RES system. The multi-faced benefits of utilizing MΦ as
delivery vehicles have been demonstrated in a study by Escobar et al.
[182] They used a spontaneous BC mouse model (MMTV-PyMT),
wherein they performed hematopoietic stem cell transplants with se
lective expression of IFNα in TIE2+ tumor-associated MΦs in the model.
The highly localized TIE2+-MΦ-mediated delivery of IFNα reduced lung
metastatic areas 5-fold and primary tumor size 3-fold without apparent
toxic effects to the host organism. The plasticity and versatility of
autologous macrophages make them ideal candidates for novel drug
delivery systems to enhance the specificity of cell therapeutics
[181–183].

acheived using 4T1 solid tumors [190]. In another study by the same
group, they constructed a polymer-lipid-peptide-based drug delivery
system (comprised of matrix metalloproteinase 2 (MMP2)-cleavable
peptides, lecithins, and PEGylated phospholipids to form an
enzyme-responsive drug release known as PLP-D-R) to co-deliver a
platelet-depleting antibody (R300) and chemotherapeutic drug, DOX.
They successfully demonstrated the anti-cancer efficacy of PLP-D-R in an
MCF7 tumor-bearing nude mouse model that showed enhanced tumor
suppression with minimal bleeding complications. Moreover, they also
showed enhanced nanoparticle retention (almost thrice as compared to
control groups), tumor regression, and metastasis inhibition in
tumor-associated platelet depleted models of mice [146,147].
Novel strategies involving anti-platelet therapeutics are gathering
momentum and emerging as an alternative approach to conventional
anti-cancer modalities. In a recent study, it was demonstrated that the
administration of low-dose aspirin, a member of nonsteroidal antiinflammatory drugs which inhibit prostanoid biosynthesis by inhibit
ing the action of COX-1 and COX-2, reduced the formation of lung me
tastases [148,191]. It was also shown that in P2Y12-deficient mice,
which is an ADP platelet receptor, the co-administration of the drug
clopidogrel with aspirin attenuates the development of hep
atocarcinoma and improves survival rates of the host [192,193]. In a
murine model of lung cancer, it was shown that how blocking the
platelet GPIIb/IIIa receptor, using the monoclonal antibody 10E5, pre
vented the cells from metastasizing [194,195]. The curative effect of
heparin and fondaparinux against tumor cells was demonstrated by in
direct inhibition of thrombin and Factor Xa, thereby inhibiting the
activation of platelets by BC cells [151]. Additional studies [196–198]
designed nano construct that can bind simultaneously to GPIIb-IIa like
integrins and P-selectin on the high-metastatic MDA-MB-231 human BC
cells. They successfully achieved their goal of killing the tumor cells and
enhanced the therapeutic efficiency by their platelet-inspired meta
stasis-targeted drug delivery approach. All the above studies establish
the potential of utilizing platelets as delivery vehicles and the promising
future of platelet-inspired anti-cancer therapeutics.
4.2. Cell-membrane coated nanoparticles for targeted delivery
Cell membranes isolated from the parent cells are subjected to a
continuous process, to isolate the various cellular components. Cells are
previously treated with hypotonic buffer under the protection of pro
tease inhibitors are followed by series of ultracentrifugation. This en
ables the removal of cell contents, including enzymes, nucleus, and
other cellular components. The membranes are then coated on the sur
face of the nanoparticle core, via extrusion, sonication, and/or electro
poration techniques (Fig. 4).
An array of various techniques that could be employed to isolate
membranes from the source cells by different methods: sonication, the
freeze-thaw method, extrusion by differential centrifugation, hypotonic
lysis buffer and/or Dounce homogenization to generate the empty cell
membrane vesicles. Such strategies would also efficiently minimize offtargeting problems, maximize the therapeutic window and would
ensure maximum survival rate and improve the quality of the patient’s
life. These systems can show enhanced specificity for cancer cells with
minimal side-effects, increasing the therapeutic efficacy up to 100-fold
against drug-resistant cancer stem cells [148]. The reappearance of
cancer after a post-treatment and disease-free period is the result of
inappropriate drug targeting and low cancer selectivity [192,194].
Thus, the application of nano-carriers for active targeting in cancer drug
delivery will exponentially alleviate the non-specific accumulation of
fering enhancement of therapeutic efficiency [147,151]. The distin
guished physical and chemical properties of these nanoparticles make
them the appropriate drug delivery carriers. These include their rigidity,
hydrophobicity, size, and charge, which facilitates their penetration into
biological barriers and effectively delivers the drug at tumor sites [196,
199,200]. These approaches have allowed alteration in the

4.1.5. Thrombocytes
Platelets are nucleated, small subcellular fragments of megakaryo
cytes with a half-life of 7–10 days that circulate in the bloodstream and
are activated during a vascular endothelial dysfunction or damage
[184]. They are associated with inflammatory cells and play a central
role in the cancer microenvironment by cell-cell communication and
ability to uptake a plethora of different molecules [185–187]. Activated
platelets are key contributors to tumorigenesis, metastasis, tumor
growth, and angiogenesis. B-thromboglobin and P-selectin, markers of
platelet activation, are abundant in patients with BC/TNBC, suggesting
tumor cell-induced platelet aggregation [188]. Once activated, these
platelets facilitate cancer cell survival and their adhesion to the endo
thelium. Thus, tumor-associated platelets can be potential therapeutic
targets and serve as effective delivery vehicles in anti-cancer treatment
modalities [188,189]. Targeting specific platelet receptors and
tumor-associated platelets has become an emergent field of delivery of
anti-tumor therapeutics. Zhang et al. [190] designed a biocompatible
liposomal nanoparticle with a tumor-homing peptide on the surface and
loaded with the reversible platelet inhibitor ticagrelor, known as
CREKA-Lipo-T, to demonstrate its ability to block tumor cell acquisition
of an invasive phenotype and tumor cell adhesion of platelets. The target
specificity and therapeutic efficiency of CREKA-Lipo-T was sucessfully
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Fig. 4. Schematic illustration of the
preparation of cell membranes and
cellular
membrane-cloaked
nano
particles. Step 1 requires selection of
appropriate cell type and extraction
method (sonication, freeze thaw, hypo
tonic lysis, extrusion, or dounce ho
mogenization). Step 2 needs removal of
inherent cellular components. After Step
2 it is often required to incorporate the
nanoparticle into the cellular membrane
immediately, to prevent the cellular
membrane lacking the intercellular
components from collapsing.

pharmacokinetics and biodistribution of the drug [199]. The previous
issues of poor solubility and low bioavailability of the conventional
anticancer drugs have been overcome by nano-formulating them [201].
They can not only conjugate the required targeting therapeutic agents
but can also deliver it without compromising its activity [202]. This
makes nanotechnology one of the best man-made achievements of
recent times. It has changed the face of diagnosis and treatment of fatal
diseases. The upcoming sections focus on cells as therapeutic carriers
and biomimetic (cell membrane cloaked) nanoparticles for tumor
directed delivery applications.
Different types of source cells are employed to generate empty cell
membrane nanovesicles that are extracted from either erythrocytes/
RBC, leukocytes: neutrophils, monocytes/macrophages, T-lymphocytes,

thrombocytes/platelets, mesenchymal stem cells, and cancer cells.
These membrane-derived vesicles retain the surface protein, antigens
from the source cells when coated on the surface of nanoparticles, can
directly target or bind to the target site of cancer (Fig. 5). The cellular
biomembranes impart a double layer, owing to the structure of the lipid
bilayer and are about 50–800 nm in size [203,204]. The transmembrane
proteins and all the relevant membrane-bound antigen required for
imparting a biological characteristic are preserved on the cell mem
brane, with no loss in functionality during or after translocating the
membrane onto the surface of the nanoparticles [205]. This allows the
nanoparticles to be camouflaged by the cell membranes, preventing
degradation by the patient’s immune system [206]. The cell membrane
coated nanoparticles can interact with cells of the targeted site, due to

Fig. 5. Schematic representation of
bioengineering of the cell membrane
cloaked drug loaded nanoparticles.
Various methods (co-extrusion, micro
fluidic electroporation, cell membrane
template polymerization) are present to
coat or decorate cellular membranes on
nanoparticles (not shown in this sche
matic). Depending on the nature and
type of cell membrane carrier that is
used the choice of drug could be made,
ranging from both hydrophilic or hy
drophobic
drug
molecules
(eg:
liposomes).
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the presence of receptors originated from the derived parent cells that
make them able to deliver therapeutics at these targeted sites [207].
Thus, cellular membranes coated nanoparticles offer advantages in
contrast to plain nanoparticles; such as i) prolonged circulation [208] ii)
cell targeting [209], iii) circumventing the immune system clearance
[210], iv) detoxification [211], and v) mediating intracellular commu
nications via endocytosis, which can be used to deliver microRNA,
mRNA [212]. However, scalability, production, isolation of these
membranes for a bulk manufacturing process needs to be addressed for
better clinical applications.

nanoparticles over erythrocytes as carriers has been documented by Xia
et al. [217].
4.2.2. Neutrophil membrane-formed nanoparticles
Neutrophils are the most commonly found leukocytes in humans.
They are the first immune cells that migrate to any infected site caused
by bacteria and virus, to prevent the pathogens from spreading, by the
release of cytokines/chemokines and ROS production. This response is
called acute inflammation and involves neutrophil infiltration, which is
regulated by intercellular interaction due to the presence of adhesion
molecules on the neutrophils and vascular endothelium [218]. For
example, researchers have demonstrated how activated neutrophils
which express integrin β2 binds to the inflamed vasculature that over
express ICAM-1 [219]. A similar approach of conjugating nanoparticles
to anti-ICAM-1 has also been explored by various researchers, however,
the conjugation process did not show significant targeting improvement
due to the complex tumor microenvironment [220]. Also, the cost
ineffectiveness makes this strategy less useful and makes avenue for
exploring the other potential options for novel targeting approach, such
as cell membrane-based or whole-cell nanoparticles. Gao et al. [221]
shows how human leukemia HL-60 cells were utilized for generating
nanovesicles by nitrogen cavitation method, which highly express
integrin β2 and binds to the inflamed vascular endothelium due to the
overexpression of ICAM-1 on them. The authors loaded the nanovesicles
with an anti-inflammatory drug (TPCA-1) to show the ability of these
nanovesicles to reduce the expression of cytokines TNF-α and IL-6,
demonstrating their ability to bind to the inflamed vasculature and
producing an anti-inflammatory effect. Red blood cells were used as a
control to generate nanovesicles that lacked the expression of integrin β2
and does not bind to the endothelium, elucidating the utilization of
neutrophils to deliver therapeutics specifically at inflamed vasculature.
Another similar study was demonstrated by Kang et al. [222] utilizing
polymeric nanoparticles coated with the neutrophil membrane to target
tumor vasculature and metastatic tumor cells in 4T1 BC with lung
metastasis model. The authors demonstrate PLGA nanoparticles when
coated with neutrophil membrane and loaded with carfilzomib, a pro
teasome inhibitor targets the circulating tumor cells or the metastatic
niche and the inflamed endothelium. Thus, demonstrating the potential
of polymeric nanoparticle coated with neutrophil membrane can be
used to inhibit early metastasis and preformed metastasis.

4.2.1. Erythrocyte membrane-coated nanoparticles
Erythrocytes are the most common cell component with a unique
biconcave discoidal shape, allowing a large volume of therapeutic cargo
to be loaded. They bear high mechanical flexibility allowing them to be
able to squeeze through very small blood capillaries even when main
taining the constant surface area. It can circulate about over 100–120
days and eventually cleared by the RES [160]. Additionally, they pre
vent unwanted macrophage uptake, provides specificity to the target,
extend biocompatibility, biodegradability, and non-immunogenic na
ture, and limits activation of other competitor cellular components
[213]. Erythrocytes membrane coated nanoparticles are prepared by
extracting the membrane from the cellular components, yet preserving
their original protein antigens, that provides the innate natural targeting
ability. Researchers have utilized hypotonic solution to extract the
cellular contents and used the membrane to coat PLGA polymer nano
particles. This construct demonstrated the prolonged circulation of 72 h
over non coated PLGA nanoparticles [208] and suppress 98% lung
metastasis in metastatic BC model. Su et al. [214] demonstrated similar
results, erythrocytes membrane coated PLGA nanoparticles prolong
circulation due to protein receptors present on the surface of these
membranes and also in combination with integrating iRGD that provide
specific targeting of metastatic breast tumor model. The authors show
inhibition of more than 90% tumor growth and 95% of the lung
metastasis with these nanoparticles as they can escape clearance by RES
and circulate longer.
Additionally, the presence of tumor penetrating peptide iRGD serves
as a receptor for lung metastatic sites that overexpress αvβ3 integrin and
neuropilin-1, which allows the nanoparticle to specifically target and
penetrate tumors. The authors also report enhanced retention of mem
brane coated nanoparticles at the metastatic regions, without the iRGD
peptide, indicating the innate tendency of the erythrocytes membrane
proteins to accumulate near the metastatic and tumor region [214]. Guo
et al. [215] developed a nano vaccine utilizing the ability of erythrocytes
coated nanoparticles to target antigen-presenting cells (especially den
dritic cells) for induction of cytotoxic T lymphocyte-mediated response
against tumors. The authors developed PLGA nanoparticles, coated with
erythrocyte membrane entraps melanoma-associated antigenic peptide
and targets dendritic cells because of their ability to specifically target
tumor antigens that promote the secretion of pro-inflammatory cyto
kines such as TNF-α and IFN-γ and causes enhanced CD8+ T-cell
response. This novel antigenic peptide delivery system retarded tumor
growth and suppressed tumor metastasis in a prophylactic, therapeutic,
and metastatic melanoma model. This illustrates the possibility of using
erythrocytes derived membranes in the development of biomimetic
nanoparticles to demonstrate tumor-specific immune response. Hybrid
nanoparticle infusing two types of bioinspired membranes: erythrocytes
and platelets for prolonging circulation time and the other for expression
of adhesion proteins, respectively increases site-specific targetability
and prevents unwanted macrophage uptake [216]. This study demon
strates the ability to fuse two different types of cell membrane into one
nanoparticle construct that will possess individual properties of each
type of membrane and the endless number of possibilities that could be
further explored. RBC membrane derived membrane-coated nano
particles are extensively studied for various applications. A detailed
overview of advantages and limitation of membrane-coated

4.2.3. Monocyte-derived nanoparticles
Monocytes are circulating white blood cells and play a crucial role in
the inflammatory response and represent around 10% of leukocytes.
They differentiate into macrophages or dendritic cells, with the latter
mainly occurring during the active infection [223]. They also have
similar roles as neutrophils and platelets in maintaining homeostasis and
inflammatory response. Monocytes have 1–3 days half-life and could be
exploited due to their intrinsic targeting ability especially at the
inflamed vasculature or injury site [224]. Researchers have explored
monocytes derived nanovesicles and have shown that these serve as
better drug delivery tools over drug-loaded exosomes for various disease
conditions. Jang et al. [225] loaded doxorubicin in exosome derived
nanovesicles and show similar inhibition in tumor growth as a 20-fold
higher dose of the same drug without causing any systemic adverse ef
fects. The exosomes nanovesicles possess counter receptors such as
LFA-1 that has specificity for cell adhesion molecules such as ICAM-1,
VCAM-1, and E-selectin that is overexpressed on the inflamed endo
thelium cells, enabling the monocytes to target the circulating cells
causing the maximal release of the therapeutic cargo at the targeted site
[225]. On a similar approach, PLGA nanoparticles loaded with doxo
rubicin and coated with monocytes that express α4β1 integrin and binds
to the cell adhesion molecules such as VCAM-1 that is overexpressed on
the metastatic cancer cells have also been explored [226]. Further
application of monocytes derived vesicles for the theranostic purpose
has also been explored and has shown to cause significantly higher
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uptake in the brain for upto 5 h, in contrast to non coated nanoparticles
[227]. This type of construct has also been explored for delivery of
siRNA and RNAi, due to the failed attempts to deliver naked RNA which
gets degraded and cannot pass through the membranes to make it to the
targeted site. Thus, this construct has improved delivery of RNA mole
cules which further can go through the process of RNA interference and
suppress overexpressed oncogenes especially in cancer [228,229]. The
ability of circulating monocytes to target tumor cells due to the
expression of protein molecules on the surface of these monocytes, make
them specific to the cells that prevent cancer progression, metastasis,
angiogenesis, invasion, migration, and resistance to chemotherapy
[230].

5. Conclusions and future perspectives
To date, TNBC remains a disease with a poor prognosis and poorer
patient outcomes because of the disparity in molecular and genomic
profiles among TNBC patients. Although major advancement has been
made with targeted therapy for other types of BC, such as for HER2
positive trastuzumab has proven to be a blessing, yet in the case of
TNBC, chemotherapy remains the backbone treatment regimen. A ray of
hope in the advancement of therapy for TNBC had emerged when FDA
approved the first-ever targeted therapy: PARP inhibitors, olaparib and
talazoparib in 2018. Although it is only restricted among patients with
BRCA1/2 mutation, which accounts for only 10–15% among TNBC
population, extensive research is ongoing leading to positive preclinical
and clinical outcomes with combination therapy or targeted therapy or
immunotherapy or ADC. However, a lot of improvement could be ach
ieved with other novel and/or nano formulation-based therapies that
could lead to greater hope in enhancing treatment options and health
outcomes among TNBC patients.
We present our views and recent development of cell membrane
cloaked nanoparticles and illustrated their application in cancer thera
peutics, particularly in BC and TNBC. These bioactive systems can also
be tested or applied for other tumor types. The selection of cell mem
brane and composition is critical to achieve a superior tumor targeting.
The unique properties (escaping the immune system and achieve long
circulation time, inherent biocompatibility and biodegradability, avoid
use of pharmaceutical excipients/additives, prolong life span, adhesion,
and homologous targeting, etc.) of source cells (RBCs, WBCs, platelets,
stem cells, immune cells, and cancer cells, etc.) can be extended as a
carrier for delivery of therapeutics. However, these whole cells suffer
from poor drug/therapeutic loading and its structure is destroyed during
loading process. Thus, nanoparticles coated with appropriate cellular
membranes can lead to the development of biomimetic nanoplatforms
which offers low immunogenicity and superior biocompatibility. The
prime advantage of these biomimetic nanosystems is retaining the
cellular vesicle structures (membrane proteins, glycans, and lipids)
which introduces the whole cell properties to the nanosystems. Such
biomimetic nanoplatforms have been widely adopted in drug delivery,
imaging, and anti-cancer research. These data laid a foundation for
designing personalized medicine. Together, membrane cloaked nano
particle technology has been matured to improve preparation, yields,
stabilization, and scaling up process. The futuristic approach may be to
introduce mixed types of cell membranes on nanoparticles rather from a
cell as coating components for effective tumor targeting. The reviewed
literature suggests that therapeutic formulations of membrane cloaked
bioactive nanoformulations do not show systemic toxicities over free
drugs. It may be possible that extensive and repeated use of such
bioactive nanosystems can induce inflammation and alteration of the
immune system. However, their long term systemic toxicity has not been
studied in humans. Thus for effective implementation of these bio
mimetic nanoplatforms in drug delivery systems, it is important to focus
on their future translation into the clinic.

4.2.4. Platelet membrane-coated nanoparticles
Platelets are small and non-nucleated cytoplasmic body that are
present actively circulating in the blood. They express a wide variety of
immune cell receptors and adhesion molecules on their surface,
responsible for mediating immune response. The platelets have the
unique ability to be recruited instantaneously at the site of injury or after
an infection which allows them to bind to the antigens and release blood
clotting factors that would heal the wound. The presence of these
various protein antigens on their surface allow immunomodulatory and
cell adhesion capability. Researchers have utilized platelet membrane
coated PLGA nanoparticles in two disease models of coronary restenosis
and systemic bacterial infection to deliver docetaxel and vancomycin,
respectively. Enhanced therapeutic efficacy was achieved via these
novel biomembranes inspired polymeric nanoparticles in contrast to
uncoated nanoparticles. Also, the authors demonstrate the coating
shields the polymeric nanoparticles from unwantedly up taken by
macrophages, thus enhancing nanoparticle deposition at the target site
[231]. DOX loaded in platelet coated liposomes with two peptides:
GPIIb-IIIa-like integrins and P-selectins expressed on their surface. This
construct shows enhanced targetability to bind and destroy specifically
metastatic BC cells over nonmetastatic BC cells in in vitro and in vivo
models [232]. Platelet coated PLGA nanoparticles that have over
expression of P-selectin was also used to deliver tumor-specific apop
tosis-inducing ligand cytokine (TRAIL) and doxorubicin to tumor cells
due to specificity for CD44 receptors, expressed on the surface of tumor
cells. Due to the enhanced targetability between the platelet membrane
and cancer cells, the therapeutic efficacy of TRAIL due to activated
extrinsic apoptosis is enhanced resulting in increased apoptosis. This
way the authors synergistically deliver active therapeutics to the tumor
cells by targeting via both intrinsic and extrinsic pathways, eliminating
metastatic cells too [233]. Similar approaches were made by synthe
sizing silica nanoparticles that were further functionalized with acti
vated platelet membranes and decorated with tumor-specific peptides
such as TRAIL. This construct was able to specifically target circulating
tumor cells and prevents unwanted phagocytosis, due to the expression
of CD47 on the surface of the activated platelets that extends the half-life
of the nanoparticles. This targeting strategy binds to circulating meta
static cells and shows significant decrease of lung metastases in meta
static orthotopic BC mouse model [234].
Platelets coated magnetic nanoparticles were applied for theranostic
applications for both cancer therapy and cancer diagnosis. The authors,
fabricated Fe3O4 nanoparticles coated with platelet membranes that
express protein moieties which allows longer circulation and prevents
immunogenicity. The application of magnetic nanoparticles allow op
tical absorption that extends to tumor magnetic resonance imaging as
well as photothermal therapy. This allows enhanced tumor targetability
along with intrinsic targeting ability from the membrane proteins of the
platelets also reducing macrophage uptake. Thus, this strategy provides
the application of bioinspired nanoparticle for personalized medicine in
various disease states [235].
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S. Strieth, C. Dunau, U. Michaelis, L. Jäger, D. Gellrich, B. Wollenberg, M. Dellian,
Phase I/II clinical study on safety and antivascular effects of paclitaxel
encapsulated in cationic liposomes for targeted therapy in advanced head and
neck cancer, Head Neck 36 (7) (2014) 976–984.
A. Awada, I. Bondarenko, J. Bonneterre, E. Nowara, J. Ferrero, A. Bakshi,
C. Wilke, M. Piccart, C.S. Group, A randomized controlled phase II trial of a novel
composition of paclitaxel embedded into neutral and cationic lipids targeting
tumor endothelial cells in advanced triple-negative breast cancer (TNBC), Ann.
Oncol. 25 (4) (2014) 824–831.
NIH, Trial of Neoadjuvants EndoTAG-1 in Combination with Paclitaxel in HER2Negative Breast Cancer (EndoTAG-1), 2013.
NIH, Carboplatin and Paclitaxel with or without Atezolizumab before Surgery in
Treating Patients with Newly Diagnosed, Stage II-III Triple-Negative Breast
Cancer, 2016.
A. Keshavarz, A. Alobaida, I.F. McMurtry, E. Nozik-Grayck, K.R. Stenmark,
F. Ahsan, CAR, a homing peptide, prolongs pulmonary preferential vasodilation
by increasing pulmonary retention and reducing systemic absorption of liposomal
fasudil, Mol. Pharm. 16 (8) (2019) 3414–3429.
J. Rashid, K. Nahar, S. Raut, A. Keshavarz, F. Ahsan, Fasudil and DETA NONOate,
loaded in a peptide-modified liposomal carrier, slow PAH progression upon
pulmonary delivery, Mol. Pharm. 15 (5) (2018) 1755–1765.
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